clinical trial · NCT07219407
A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures
Focal EpilepsyEpilepsyRefractory Focal EpilepsySeizureFocal SeizureFocal Onset SeizureRAP-219
brief summary
This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.
started
Dec 15, 2025
primary completion
Feb 3, 2028
completion
Feb 3, 2028
last updated
Jan 23, 2026
detailed description
This is a multi-center, open-label study to evaluate the long-term safety, tolerability, pharmacokinetics, pharmacodynamics and antiseizure activity of RAP-219 in adult participants with refractory focal seizures
official title
An Open-label, Long-term Study Evaluating RAP-219 in Adult Participants With Refractory Onset Seizures
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol